1-12 of 12
Adam V. Patterson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers

Vijaya G. Tirunagaru, Adriana Estrada-Bernal, Hui Yu, Chris Rivard, Fred Hirsch, Matthew Bull, Maria Abbatista, Jeff Smaill, Adam V. Patterson, Robert C. Doebele, Avanish Vellanki
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2202.
https://doi.org/10.1158/1538-7445.AM2019-2202
Published: 01 July 2019
View articletitled, Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers
Journal Articles

Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial

Adam V. Patterson, Shevan Silva, Christopher Guise, Maria Abbattista, Matthew Bull, Huai-Ling Hsu, Charles Hart, Jessica Sun, Angus Grey, Amir Ashoorzadeh, Robert Anderson, Jeff B. Smaill
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 5358.
https://doi.org/10.1158/1538-7445.AM2015-5358
Published: 01 August 2015
View articletitled, Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial
Journal Articles

Abstract 2111: Identification of reductases capable of metabolic activation of hypoxia targeting prodrug SN30000 and hypoxia marker EF5.

Jingli Wang, Chris P. Guise, Huai-Ling Hsu, Daniel Hurley, William R. Wilson, Adam V. Patterson
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 2111.
https://doi.org/10.1158/1538-7445.AM2013-2111
Published: 15 April 2013
View articletitled, Abstract 2111: Identification of reductases capable of metabolic activation of hypoxia targeting prodrug SN30000 and hypoxia marker EF5.
Journal Articles

Abstract LB-297: Characterization of novel hypoxia-activated prodrugs of irreversible pan-HER inhibitors

Guo-Liang Lu, Jeff B. Smaill, Maria Abbattisia, Robert F. Anderson, Amir Ashoorzadeh, William A. Denny, Fernando Doñate, Annie Hsu, Jagdish Jaiswal, Stephen Jamieson, Ho H. Lee, Andrej Maroz, Sunali Mehta, Alison Pruijn, Sophie P. Syddall, Aaron Thompson, Wouter van Leeuwen, William R. Wilson, Adam V. Patterson
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): LB-297.
https://doi.org/10.1158/1538-7445.AM10-LB-297
Published: 15 April 2010
View articletitled, Abstract LB-297: Characterization of novel hypoxia-activated prodrugs of irreversible pan-HER inhibitors
Journal Articles

Abstract 453: Identification of human oxidoreductases involved in the hypoxia-dependent activation of bioreductive prodrugs

Christopher P. Guise, Smitha R. Tipparaju, Maria R. Abbattista, Gabi U. Dachs, Jiechuang Su, Annika B. Foehrenbacher, William R. Wilson, Adam V. Patterson
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 453.
https://doi.org/10.1158/1538-7445.AM10-453
Published: 15 April 2010
View articletitled, Abstract 453: Identification of human oxidoreductases involved in the hypoxia-dependent activation of bioreductive prodrugs
Journal Articles

Abstract 41: Role of the novel glucose-phosphorylating enzyme ADP-dependent glucokinase in human cancer cell lines featuring knockouts generated by zinc finger nucleases

Susan Richter, Adam V. Patterson, Kathryn M. Stowell, Ron S. Ronimus, William R. Wilson
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 41.
https://doi.org/10.1158/1538-7445.AM10-41
Published: 15 April 2010
View articletitled, Abstract 41: Role of the novel glucose-phosphorylating enzyme ADP-dependent glucokinase in human cancer cell lines featuring knockouts generated by zinc finger nucleases
Journal Articles

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

Christopher P. Guise, Maria R. Abbattista, Rachelle S. Singleton, Samuel D. Holford, Joanna Connolly, Gabi U. Dachs, Stephen B. Fox, Robert Pollock, Justin Harvey, Parry Guilford, Fernando Doñate, William R. Wilson, Adam V. Patterson
Journal: Cancer Research
Cancer Res (2010) 70 (4): 1573–1584.
https://doi.org/10.1158/0008-5472.CAN-09-3237
Published: 14 February 2010
View articletitled, The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3
Open the PDF for The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3 in another window
Includes: Supplementary data
Journal Articles

DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity

Rachelle S. Singleton, Christopher P. Guise, Dianne M. Ferry, Susan M. Pullen, Mary J. Dorie, J. Martin Brown, Adam V. Patterson, William R. Wilson
Journal: Cancer Research
Cancer Res (2009) 69 (9): 3884–3891.
https://doi.org/10.1158/0008-5472.CAN-08-4023
Published: 30 April 2009
View articletitled, DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity
Open the PDF for DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity in another window
Includes: Supplementary data
Journal Articles

Optimized Clostridium-Directed Enzyme Prodrug Therapy Improves the Antitumor Activity of the Novel DNA Cross-Linking Agent PR-104

Shie-Chau Liu, G-One Ahn, Mitomu Kioi, Mary-Jo Dorie, Adam V. Patterson, J. Martin Brown
Journal: Cancer Research
Cancer Res (2008) 68 (19): 7995–8003.
https://doi.org/10.1158/0008-5472.CAN-08-1698
Published: 30 September 2008
View articletitled, Optimized Clostridium-Directed Enzyme Prodrug Therapy Improves the Antitumor Activity of the Novel DNA Cross-Linking Agent PR-104
Open the PDF for Optimized Clostridium-Directed Enzyme Prodrug Therapy Improves the Antitumor Activity of the Novel DNA Cross-Linking Agent PR-104 in another window
Includes: Supplementary data
Journal Articles

Extracellular metabolites of hypoxia-selective dinitrobenzamide mustard prodrugs and their role in bystander effects

William R. Wilson, Susan M. Pullen, Dianne M. Ferry, Rachelle Douglas, Bronwyn G. Siim, William A. Denny, Graham J. Atwell, Shangjin Yang, Frederik B. Pruijn, Biljana Petrovic-Stojanovska, Shelley Edmunds, Sophie Valentine, Sally Bai, Adam V. Patterson
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 321.
Published: 01 May 2005
View articletitled, Extracellular metabolites of hypoxia-selective dinitrobenzamide mustard prodrugs and their role in bystander effects
Journal Articles

Human NADPH-Cytochrome P450 Reductase Overexpression Does Not Enhance the Aerobic Cytotoxicity of Doxorubicin in Human Breast Cancer Cell Lines

Shairoz Ramji, Chunja Lee, Tadanobu Inaba, Adam V. Patterson, David S. Riddick
Journal: Cancer Research
Cancer Res (2003) 63 (20): 6914–6919.
Published: 28 October 2003
View articletitled, Human NADPH-Cytochrome P450 Reductase Overexpression Does Not Enhance the Aerobic Cytotoxicity of Doxorubicin in Human Breast Cancer Cell Lines
Open the PDF for Human NADPH-Cytochrome P450 Reductase Overexpression Does Not Enhance the Aerobic Cytotoxicity of Doxorubicin in Human Breast Cancer Cell Lines in another window
Journal Articles

Thymidine Phosphorylase Moderates Thymidine-dependent Rescue after Exposure to the Thymidylate Synthase Inhibitor ZD1694 (Tomudex) in Vitro

Adam V. Patterson, Denis C. Talbot, Ian J. Stratford, Adrian L. Harris
Journal: Cancer Research
Cancer Res (1998) 58 (13): 2737–2740.
Published: 01 July 1998
View articletitled, Thymidine Phosphorylase Moderates Thymidine-dependent Rescue after Exposure to the Thymidylate Synthase Inhibitor ZD1694 (Tomudex) in Vitro
Open the PDF for Thymidine Phosphorylase Moderates Thymidine-dependent Rescue after Exposure to the Thymidylate Synthase Inhibitor ZD1694 (Tomudex) in Vitro in another window